PHASIQ has been awarded a $750,000 grant by the National Science Foundation. This Small Business Innovation Research grant is a phase II project, starting April 1 2015 through March 31, 2017.
PHASIQ’s Director of Product Development, John Dishinger Ph.D. is the Principal Investigator on Development of a robust multiplex protein test for cardiovascular disease research. This project supports the further development of PHASIQ’s proprietary biomarker test platform. The project scope includes the creation of a novel multiplex assay kit (plate, reagents, and standards) for cardiovascular disease assessment from patient blood. We are developing this test in concert with researchers at the University of Michigan who are making their banked, de-identified patient samples available for test development and analysis.
Our Phase I project concluded with a successful prototype, and the Phase II project extends our cross-reaction free multiplex ELISA technology to a cardiovascular disease application.